ConvaTec Group’s Acquisition of Triad Life Sciences

Ropes & Gray represented ConvaTec Group in the transaction.

ConvaTec Group, a global medical solutions company, executed its acquisition of medical device company, Triad Life Sciences. 

Under the merger agreement, which is subject to Hart-Scott-Rodino approval, ConvaTec will pay $125 million at closing, followed by two payments of $25 million each if certain short-term milestones are reached, and additional potential payments of up to $275 million if certain financial performance targets are met within the first two years. 

ConvaTec is a FTSE 250 global medical products and technologies company focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. 

Triad Life Sciences is a science-driven, patient-focused biotech company dedicated to the innovation of tissue-based solutions for the treatment of acute or chronic wounds, soft tissue injuries, and other regenerative applications. 

The Ropes team that represented ConvaTec was led by mergers & acquisitions partner Timothy Castelli (Chicago; Picture) and corporate associate Andrew Pomranke (Chicago), and included IP transactions partner Melissa Rones (Boston), health care partner Christina Bergeron (Boston), benefits partner Matt Jones (Chicago), life sciences regulatory partner Kellie Combs (Washington, D.C.), IP transactions counsel Ryan Murphey (New York), litigation & enforcement counsel Bill Kearney (Washington, D.C.), antitrust partner Jane Willis (Boston) and tax partner Benjamin Rogers (San Francisco).

Involved fees earner: Christina Bergeron – Ropes & Gray; Timothy Castelli – Ropes & Gray; Kellie Combs – Ropes & Gray; Matthew Jones – Ropes & Gray; William Kearney – Ropes & Gray; Ryan Murphey – Ropes & Gray; Andrew Pomranke – Ropes & Gray; Benjamin Rogers – Ropes & Gray; Melissa Rones – Ropes & Gray; Jane Willis – Ropes & Gray;

Law Firms: Ropes & Gray;

Clients: ConvaTec Group;